{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.60","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"60.6"},{"groupId":"OG001","spread":"15.6","value":"72.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Inhibition of DNA synthesis is defined as the percentage of DNA synthesis rate at 24-hour post-araC treatment over DNA synthesis rate pre-araC treatment.","dispersionType":"Standard Error","groups":[{"description":"High-dose Cytarabine (Ara-C) (HDAC)","id":"OG000","title":"Arm 1: (HDAC)"},{"description":"Low-dose Cytarabine (Ara-C) (LDAC)","id":"OG001","title":"Arm 2:(LDAC)"}],"paramType":"MEAN","populationDescription":"Of 232 eligible patients, 49 had DNA synthesis rate performed prior to araC treatment. Of the 49 patients, 23 had no 24-hr samples and 3 did not have enough cells in 24-hr samples. 21 patients with both pre and post araC samples were included in the DNA inhibition study. Of the 21 patients, 9 were treated on HDAC and 12 were treated on LDAC.","reportingStatus":"POSTED","timeFrame":"Measurements were assessed in Induction I chemotherapy","title":"To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy","type":"SECONDARY","unitOfMeasure":"Percent Inhibition of DNA Synthesis"}